FEROX STRATEGIES

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 18, 2025

Lobbying activity 2

Taxation/Internal Revenue Code

General issues related to rare disease treatment development.

Health Issues

General issues related to rare disease treatment.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.